We supply products to over 25 countries worldwide. Veriton Pharma focuses on the development of licensed medicines, predominantly for CNS, and unlicensed medicines for patients with special requirements that licensed products cannot meet.
The company has a portfolio of more than 60 specialised formulations for treating conditions across a range of therapeutic areas. Veriton Pharma’s products are supported in the UK by a team of Regional Account Managers who are able to access the NHS at all critical levels. Similarly, both the MEA and Australian offices are able to provide experienced sales support within each of these areas.
Licensed Products
We are committed to developing licensed medicinal products that meet the specific needs of our patients. Veriton Pharma’s portfolio of prescription medicines stems from our team’s deep expertise in the field of epilepsy.
News
- SAPHNA Annual Conference 2019: HEALTH FOR ALL CHILDREN
SAPHNA Annual Conference 2019: 18th June in Manchester We are delighted to be attending the upcoming SAPHNA Annual Conference; HEALTH FOR ALL CHILDREN – School and Public Health Nurses Turning the Tide…. Read More
- Young Epilepsy online guide for school
Veriton Pharma is pleased to announce the online publication of the charity Young Epilepsy’s online guide for schools. This comprehensive resource aimed at improving the management and support of children with epilepsy… Read More
- Young Epilepsy and Veriton Pharma Ltd announce key partnership agreement in support of the charity’s ‘Rules 4 Schools’ campaign
Young Epilepsy and Veriton Pharma Ltd (Veriton) have announced a key agreement, where the organisations will work in partnership to deliver the ‘Rules 4 Schools” element of the charity’s newly… Read More
- Epistatus® 10 Mg (In 1 Ml) Oromucosal Solution Midazolam Available on Nhs Prescription Is Approved For Use By Both the Scottish Medicines Consortium (Smc) and the All Wales Medicines Strategy Group (Awmsg)
Epistatus is licensed for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1. Epistatus… Read More